Triazinate cas no:41191-04-2

NameTriazinate
CAS41191-04-2
SynonymsTriazinate
Molecular FormulaC19H21ClN6O2 . C2H6O3S
Molecular Weight539.054

refractive index1.635

Safety

Poison by intraperitoneal route. Human systemic effects by intravenous route: somnolence, changes in bone marrow, dermatitis, visual field changes, leukopenia, thrombocytopenia, hypermotility, diarrhea, nausea or vomiting. Human mutation data reported. When heated to decomposition it emits very toxic fumes of Cl⁻, NO_x, and SO_x.

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LDLo	intravenous	40mg/kg (40mg/kg)	BEHAVIORAL: FOOD INTAKE (ANIMAL) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	National Technical Information Service. Vol. PB220-397,
human	TDLo	intravenous	8mg/kg (8mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Cancer Research. Vol. 36, Pg. 48, 1976.
human	TDLo	intravenous	20mg/kg (20mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Cancer Vol. 40, Pg. 9, 1977.
human	TDLo	intravenous	24mg/kg/5D (24mg/kg)	BLOOD: LEUKOPENIA BLOOD: THROMBOCYTOPENIA BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Cancer Vol. 38, Pg. 690, 1976.
mouse	LD50	intraperitoneal	58600ug/kg (58.6mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
women	TDLo	intravenous	1355mg/kg/13W (1355mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Archives of Dermatology. Vol. 121, Pg. 232, 1985.